Health Care [ 5/12 ] | Pharmaceuticals [ 13/73 ]
NASDAQ | Common Stock
60 Degrees Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the United States.
It offers Arakoda for malaria preventative treatment.
The company also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19 indications; Tafenoquine, which is in phase IIA clinical trials for babesiosis, fungal pneumonias, and candidiasis disease; and Celgosivir for Zika, respiratory viruses, and dengue.
It also has patent license agreement with Tufts Medical Center to jointly advance the development and commercialization of tafenoquine for the treatment and prevention of babesiosis.
The company was founded in 2010 and is headquartered in Washington, District Of Columbia.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Aug 15, 25 | -1.08 Increased by +74.49% | -0.10 Decreased by -981.70% |
| May 15, 25 | -1.55 Decreased by -5.27 K% | -0.11 Decreased by -1.31 K% |
| Feb 26, 25 | -2.16 Decreased by -526.09% | -0.18 Decreased by -1.10 K% |
| Nov 14, 24 | -0.93 Decreased by -220.78% | -0.22 Decreased by -322.73% |
| Aug 28, 24 | -4.24 Decreased by -285.45% | -0.21 Decreased by -1.92 K% |
| May 15, 24 | 0.03 | -0.15 Increased by +120.00% |
| Feb 28, 24 | -0.34 | -0.14 Decreased by -146.43% |
| Nov 20, 23 | 0.77 | 0.95 Decreased by -18.95% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Jun 30, 25 | 307.87 K Increased by +144.93% | -1.72 M Increased by +58.86% | Decreased by -557.53% Increased by +83.20% |
| Mar 31, 25 | 256.28 K Increased by +75.42% | -1.88 M Decreased by -535.93% | Decreased by -732.22% Decreased by -348.50% |
| Dec 31, 24 | 261.44 K Increased by +512.17% | -2.05 M Decreased by -4.44% | Decreased by -782.22% Increased by +82.94% |
| Sep 30, 24 | 135.29 K Increased by +164.31% | -2.16 M Decreased by -151.63% | Decreased by -1.60 K% Decreased by -119.53% |
| Jun 30, 24 | 125.70 K Increased by +111.15% | -4.17 M Decreased by -25.06% | Decreased by -3.32 K% Increased by +40.77% |
| Mar 31, 24 | 146.09 K Increased by +750.77% | 430.47 K Increased by +116.56% | Increased by +294.65% Increased by +101.95% |
| Dec 31, 23 | 42.71 K Increased by +156.45% | -1.96 M Decreased by -1.80% | Decreased by -4.58 K% Decreased by -280.32% |
| Sep 30, 23 | 51.19 K Decreased by -69.56% | 4.18 M Increased by +389.00% | Increased by +8.17 K% Increased by +1.05 K% |